Program
trospium chloride
Also written as “Xanomeline/trospium chloride”, “Xanomeline/Trospium Chloride Capsule” and “Xanomeline/Trospium Chloride”.
Its studies are mostly in Schizophrenia · Urinary Bladder, Overactive · Alzheimer Disease · Mania · Pulmonary Disease, Chronic Obstructive, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 97 open or running | phase 4since Oct 13, 2025 | Jul 6, 2016 | Dec 3, 2026phase 1 · NCT07204418 |
| AbbVie | 50 open or running | phase 4since Mar 16, 2009 | Mar 16, 2009 | none ahead |
| Keenova Therapeutics | 10 open or running | phase 2since Apr 24, 2007 | Apr 24, 2007 | none ahead |
Also a collaborator on its studies: Alkermes.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 24, 2007First study: phase 2 study in Pulmonary Disease, Chronic ObstructiveNew to Keenova TherapeuticsKeenova Therapeutics · NCT00465959 · 24 enrolled · United States
- Mar 16, 2009AbbVie's first study: phase 4 study in Urinary Bladder, OveractiveNew to AbbVieAbbVie · NCT00863551 · 12 enrolled · United States
- Jul 1, 2009Phase 4 study in ObesityAbbVie · NCT00932022 · 127 enrolled · United States
- Sep 16, 2009Phase 1 study in HealthyAbbVie · NCT00986401 · 44 enrolled · United States
- Mar 17, 2010Phase 4 study in Urinary Bladder, OveractiveAbbVie · NCT01089751 · 322 enrolled · United States
- Aug 9, 2010Phase 4 study in Urinary Bladder, OveractiveAbbVie · NCT01178827 · 20 enrolled · United States
- Jul 6, 2016Bristol-Myers Squibb's first study: phase 1 study in SchizophreniaNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT02831231 · 70 enrolled · United States
- Jun 2, 20252 phase 3 studies in Alzheimer DiseaseBristol-Myers Squibb · NCT07011745, NCT07011732
- Jun 23, 2025Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT07063342 · 236 planned · United Kingdom
- Aug 21, 2025Phase 3 study in ManiaBristol-Myers Squibb · NCT07140913 · 424 planned · United States, Argentina, Bulgaria and more
- Sep 24, 2025Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT07204418 · 56 planned · United States
- Oct 13, 2025Phase 4 study in SchizophreniaBristol-Myers Squibb · NCT07221877 · 60 planned · United States
- Nov 21, 2025Phase 4 study in Healthy VolunteersBristol-Myers Squibb · NCT07257120 · 10 enrolled · United States
- Jun 30, 2026Phase 3 study in SchizophreniaBristol-Myers Squibb · NCT07686263 · 472 planned · United States, Argentina, Bulgaria and more
Ahead
- Dec 3, 2026Primary completion: phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT07204418
- Mar 29, 2027Primary completion: phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT07063342
- Jun 28, 2027Primary completion: phase 3 study in ManiaBristol-Myers Squibb · NCT07140913
- Dec 30, 2027Primary completion: phase 4 study in SchizophreniaBristol-Myers Squibb · NCT07221877
TargetBeta
“Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Glycopyrrolaterule | Novartis | phase 4 | 87 |
| trospiumrule | Bristol-Myers Squibb | phase 4 | 21 |
| Atropinerule | Laboratorios Sophia S.A de C.V. | phase 3 | 17 |
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07686263Schizophrenia · United States, Argentina, Bulgaria and more | 3 | Recruiting | Bristol-Myers Squibb | Mar 3, 2029 | 472 |
| NCT07257120Healthy Volunteers · United States | 4 | Completed | Bristol-Myers Squibb | Jun 8, 2026 | 10 |
| NCT07221877Schizophrenia · United States | 4 | Recruiting | Bristol-Myers Squibb | Dec 30, 2027 | 60 |
| NCT07204418Healthy Volunteers · United States | 1 | Recruiting | Bristol-Myers Squibb | Dec 3, 2026 | 56 |
| NCT07140913Mania · United States, Argentina, Bulgaria and more | 3 | Recruiting | Bristol-Myers Squibb | Jun 28, 2027 | 424 |
| NCT07063342Healthy Volunteers · United Kingdom | 1 | Recruiting | Bristol-Myers Squibb | Mar 29, 2027 | 236 |
| NCT07011745Alzheimer Disease · United States, Argentina, Chile and more | 3 | Recruiting | Bristol-Myers Squibb | Nov 3, 2028 | 426 |
| NCT07011732Alzheimer Disease · United States, Argentina, Brazil and more | 3 | Recruiting | Bristol-Myers Squibb | Nov 24, 2028 | 426 |
| NCT02831231Schizophrenia · United States | 1 | Completed | Bristol-Myers Squibb | Oct 28, 2016 | 70 |
| NCT01178827Urinary Bladder, Overactive · United States | 4 | Completed | AbbVie | Mar 2011 | 20 |
| NCT01089751Urinary Bladder, Overactive · United States | 4 | Completed | AbbVie | Jun 2012 | 322 |
| NCT00986401Healthy · United States | 1 | Completed | AbbVie | Nov 2009 | 44 |
| NCT00932022Obesity · United States | 4 | Completed | AbbVie | Dec 2011 | 127 |
| NCT00863551Urinary Bladder, Overactive · United States | 4 | Completed | AbbVie | Aug 2009 | 12 |
| NCT00465959Pulmonary Disease, Chronic Obstructive · United States | 2 | Completed | Keenova Therapeutics | Jun 2007 | 24 |
How it is read
Names in the registry
- “Xanomeline/trospium chloride”, 2 entries
- “Xanomeline/Trospium Chloride Capsule”, 2 entries
- “Xanomeline/Trospium Chloride”, 2 entries
- “Trospium Chloride”, 2 entries
- “trospium chloride”, 2 entries
Conditions, from the studies’ own filings
- Schizophrenia, 3 studies
- Urinary Bladder, Overactive, 3 studies
- Alzheimer Disease, 2 studies
- Mania, 1 study
- Pulmonary Disease, Chronic Obstructive, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.